Abby Jacobson
Overview
Explore the profile of Abby Jacobson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Polder K, Friedman P, Feetham J, Gower J, Lin T, Jacobson A
Dermatol Surg
. 2024 Aug;
51(1):52-57.
PMID: 39190540
Background: Nonablative lasers treat photoaged skin and stimulate new collagen formation while sparing epidermal damage. Objective: To evaluate the effectiveness and safety of nonablative fractional diode combination laser skin resurfacing...
2.
Kircik L, Jacobson A
J Drugs Dermatol
. 2024 Feb;
23(2):50-53.
PMID: 38306148
Introduction: Moisturizers are often used as adjuvant therapy for psoriasis to assist with rehydration and skin barrier restoration. Fixed-combination halobetasol propionate 0.01% and tazarotene 0.045% lotion (HP/TAZ) is indicated for...
3.
Draelos Z, Draelos M, Lin T, Jacobson A
J Dermatolog Treat
. 2023 Aug;
34(1):2245081.
PMID: 37577786
Objective: Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for the treatment of plaque psoriasis in adults, with a demonstrated efficacy and safety profile in phase 3...
4.
Lebwohl M, Koo J, Leonardi C, Armstrong A, Rawnsley N, Goehring E, et al.
J Drugs Dermatol
. 2023 Apr;
22(4):419-422.
PMID: 37026879
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. Brodalumab carries a...
5.
Kircik L, Tanghetti E, Friedman A, Kucera K, Jacobson A
J Clin Aesthet Dermatol
. 2023 Mar;
16(3):21-26.
PMID: 36950046
Objective: The fixed-dose corticosteroid/retinoid combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) is approved for topical treatment of plaque psoriasis in adults. In addition to its current indication for...
6.
Kircik L, Bhatia N, Lain E, Jacobson A
J Drugs Dermatol
. 2023 Mar;
22(3):247-251.
PMID: 36877884
Topical therapies are commonly used to treat psoriasis, either as monotherapy for milder disease or as adjuncts to systemic and biologic drugs. Topical steroids and tazarotene are both options for...
7.
Del Rosso J, Han G, Armstrong A, Michael Lewitt G, Jacobson A
J Drugs Dermatol
. 2023 Feb;
22(2):132-138.
PMID: 36745378
Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for plaque psoriasis, both as...
8.
Boh E, Kuraitis D, Jacobson A, Sikes M
Dermatol Ther (Heidelb)
. 2023 Feb;
13(3):835-842.
PMID: 36729236
Introduction: Cutaneous T-cell lymphoma (CTCL) is a rare, heterogeneous group of non-Hodgkin lymphomas characterized by various clinical, molecular, and histopathologic features of the skin. Variants of CTCL share many clinical...
9.
Fried R, Lebwohl M, Bettencourt M, Koo J, Jacobson A
J Drugs Dermatol
. 2022 Aug;
21(8):854-860.
PMID: 35946972
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions. For...
10.
Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A
Dermatol Ther (Heidelb)
. 2022 Jun;
12(6):1289-1302.
PMID: 35672564
Psoriatic involvement in areas of the body such as nails, palms and soles (palmoplantar), and scalp is associated with dramatically negative effects on quality of life relative to involvement elsewhere...